WallStSmart

Cencora Inc. (COR)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 1028% more annual revenue ($328.68B vs $29.14B). MDLN leads profitability with a 3.3% profit margin vs 0.8%. COR trades at a lower P/E of 19.6x. COR earns a higher WallStSmart Score of 64/100 (C+).

COR

Buy

64

out of 100

Grade: C+

Growth: 7.3Profit: 6.0Value: 8.0Quality: 5.0

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 5.0Value: 6.3Quality: 6.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORUndervalued (+71.1%)

Margin of Safety

+71.1%

Fair Value

$1266.50

Current Price

$261.08

$1005.42 discount

UndervaluedFair: $1266.50Overvalued
MDLNUndervalued (+69.5%)

Margin of Safety

+69.5%

Fair Value

$147.84

Current Price

$39.52

$108.32 discount

UndervaluedFair: $147.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR4 strengths · Avg: 9.0/10
Return on EquityProfitability
107.1%10/10

Every $100 of equity generates 107 in profit

EPS GrowthGrowth
128.3%10/10

Earnings expanding 128.3% YoY

PEG RatioValuation
0.738/10

Growing faster than its price suggests

Free Cash FlowQuality
$1.17B8/10

Generating 1.2B in free cash flow

MDLN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

COR4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.8%4/10

3.8% revenue growth

Profit MarginProfitability
0.8%3/10

0.8% margin — thin

Operating MarginProfitability
1.7%3/10

Operating margin of 1.7%

Price/BookValuation
26.6x2/10

Trading at 26.6x book value

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
36.7x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
6.0%3/10

ROE of 6.0% — below average capital efficiency

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, EPS Growth, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bear Case : COR

The primary concerns for COR are Revenue Growth, Profit Margin, Operating Margin. Thin 0.8% margins leave little buffer for downturns.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

MDLN is growing revenue faster at 10.7% — sustainability is the question.

COR generates stronger free cash flow (1.2B), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

COR scores higher overall (64/100 vs 52/100). MDLN offers better value entry with a 69.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?